Venture Capital & Private Equity Fund Updates:
Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 M. Fund III will be deployed to support and empower groundbreaking life sciences and medical technology companies aiming to drive innovation and improve patient outcomes. (PR)
Oaktree Capital Management, L.P. Is Betting on Life Sciences With $2.3-Billion Fundraise. This is the firm’s first dedicated life sciences fund. Non-dilutive financing said to be attractive for growing firms (bloomberg)
Public Ventures launches $100M impact fund to invest in early-stage life science, clean tech (techcrunch)
Arboretum Ventures Exceeds Target With $268 M Sixth Fund. Arboretum’s More Than Sixty Investments In Medical Devices, Diagnostics, Life Science Tools, And It‐enabled Healthcare Services Have Impacted Over 16 M Patients Nationwide. These Investments Have Spanned A Diverse Set Of Disease Areas Including Oncology, Cardiovascular, Infectious Disease, Pulmonology, Urology, And Orthopedics (Pr)
Life sciences VC firm Westlake Village BioPartners® is ready to restock its capital reserves shortly after its success with bringing portfolio company Acelyrin to one of the biggest IPOs in recent biotech memory (endpts)
Syncona Limited blames £80M drop in its biotech valuations on 'challenging market' (fiercebiotech)
UK Government ‘to unlock £75bn pension fund capital for startups’. Tech and investment community reacts to Chancellor Jeremy Hunt’s plan after nine funds agree to invest at least 5% into startups and scaleups (businesscloud)
Funding Update:
Tenpoint Therapeutics Ltd Therapeutics launches with $70M to restore vision with stem cell therapies and ‘reprogramming’ medicines, Series A led by F-Prime Capital, Sofinnova Partners, British Patient Capital, Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund (endpts)
Caribou Biosciences Announces $25 M Equity Investment from Pfizer (PR)
Kanvas Biosciences Announces $12 M Pre-Series A to Accelerate Microbiome Drug Development, DCVC led the round with participation from Lions Capital LLC, Cooke LLC, Uncommon Denominator, and Triple Impact Ventures Capital. (PR)
Camena Bioscience Closes $10m Series A Financing as Demand for DNA Synthesis Technology Increases. Funding will be used to scale operations and continue the development of its pioneering DNA synthesis platform, gSynth™ (PR)
CoJourney CO. Inc. Secures $30 M Financing and Announces Expansion of US Operations: High Quality, Cost Effective, Commercial Scale Manufacturing Platform for Cell and Gene Therapies. This funding round was led by Legend Capital君联资本 and supported by GL ventures, Legend Star 联想之星 Investment Management, and Lake Bleu Capital (PR)
Briggs Morrison's Crossbow Therapeutics, Inc Therapeutics nabs $80M from MPM BioImpact, Pfizer Ventures LLC, Eli Lilly and Company, Polaris Partners, BVF PARTNERS, L.P and Mirae Asset Global Investments in hunt for better cancer drugs (endpts)
Lion TCR Secures $40 M Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy (PR)
Recursion Pharmaceuticals soars 121% after NVIDIA invests $50 M in the biotech for AI drug discovery (PR)
Grant Funding Updates:
Developing Next-Gen Scientific Leaders: Parker Institute for Cancer Immunotherapy Awards up to $2.9 M to Eight Early Career Investigators (PR)
Children's Hospital of Philadelphia Receives $1 M Grant from Pediatric Cancer Foundation (PR)
Billions in The National Institutes of Health (NIH) grants could be jeopardized by appointments snafu, Republicans say (CBS)
$30M Camden Cancer Research Center launched between South Jersey health organizations Cooper University Health Care, the Cooper Medical School of Rowan University and the Coriell Institute for Medical Research Institute have teamed up to launch (bizjournal)
Integral Molecular Awarded $1 M by Commonwealth of Pennsylvania to Support Biotechnology Pandemic Research Center (PR)
Just - Evotec Biologics Biologics Awarded Second Contract from United States Department of Defense Under Accelerated Antibodies Program (biospace)
$22 M NIH award will accelerate ‘CRISPR’ research at University of California, Berkeley, The Ohio State University State (PR)
Akeso Therapeutics, Inc. has been awarded a SBIR Phase I grant of $398,040 from the National Cancer Institute of the NIH. This award will support our preclinical development of chimeric antigen receptor (CAR)-modified invariant Natural Killer T (iNKT) cell therapy for hematological malignancies.
The public-private consortium will fund three gene therapy clinical trials at UT Southwestern Medical Center and Children's Health. Two new gene therapy trials at UT Southwestern and Children’s Health funded through the consortium will test treatments for multiple sulfatase deficiency and Charcot-Marie-Tooth disease type 4J.(PR)
